EQS-Adhoc: SynBiotic SE completes capital increase

Inside information according to Article 17 MAR (ad hoc release)

NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN THE OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR WITHIN ANY INTENDED TO ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY.

SynBiotic SE completes capital increase

Munich, September 27, 2022 SynBiotic SE has completed the cash capital increase resolved on September 2, 2022. 142,261 new shares were placed at a subscription price of EUR 12.00 per new share. This capital increase therefore results in gross issue proceeds of EUR 1,707,132.00.

The implementation of this capital increase is expected to be entered in the company’s commercial register at the beginning of October 2022. Inclusion in trading on the primary market of the Düsseldorf Stock Exchange and delivery of the new shares is expected to take place in mid-October 2022.

The net issue proceeds from the capital increase are to be used to finance the business activities and expansion through possible participations of SynBiotic SE.

About SynBiotic SE:

SynBiotic SE is the largest listed group of companies in Europe in the hemp and cannabis sector and pursues a buy & build investment strategy focused on the EU. The group of companies covers the entire supply chain from cultivation through production to trading from the field to the shelf. A core business of the company is the research & development, production and marketing of cannabinoid and terpene-based solutions to major societal problems such as pain, sleep and anxiety. In addition to the food supplement and cosmetics market, SynBiotic SE is also active in the medical and, in the future, also in the recreational cannabis sector.

More information is available at https://www.synbiotic.com.

investor contact

Lars Mueller

[email protected]